BriaCell Therapeutics Corp. Warrant (BCTXZ)

CA — Healthcare Sector

Peers:

Automate Your Wheel Strategy on BCTXZ

With Tiblio's Option Bot, you can configure your own wheel strategy including BCTXZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol BCTXZ
Rev/Share 0.0
Book/Share 3.1967
PB 0.1323
Debt/Equity 0.0
CurrentRatio 3.4141
ROIC -1.9271

MktCap 2978535.0
FreeCF/Share -6.5669
PFCF -0.1214
PE -0.0845
Debt/Assets 0.0
DivYield 0
ROE -4.3973

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 1
P/B Score 5
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

About BriaCell Therapeutics Corp. Warrant (BCTXZ)

IPO Date 2025-04-25
Website https://www.briacell.com
Industry Biotechnology
CEO William V. Williams FCPA,
Employees 16

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.